Search
for
Sort by
Research 211–240 of 1000+
- Anagen effluvium
- Three cases of immune‐mediated adnexal skin disease treated with cyclosporin
- Patients with specific skin disorders who are affected by COVID ‐19: What do experiences say about management strategies? A systematic review
- Cocaine-related bullous disease
- Erosive Pustular Dermatosis of the Scalp Induced by Imiquimod
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Anticytokine therapy, particularly anti-IFN-γ, in Th1-mediated autoimmune diseases
- Biology of the skin and dermatological disease
- SUSPECTED CUTANEOUS DRUG TOXICITY IN RHEUMATOID ARTHRITIS—AN EVALUATION
- Skin Diseases in Horses
- Psoriatic Alopecia
- A clinical and histopathological study of cicatricial alopecia
- Cutaneous Markers of Disorders Affecting Adult Horses
- The case for case reports
- Cutaneous Reactions to Drugs
- Anagen Effluvium in Association With Extracorporeal Membrane Oxygenation
- A STUDY ON CUTANEOUS MANIFESTATIONS OF HYPOTHYROIDISM IN A TERTIARY HOSPITAL IN SOUTH INDIA
- An unusual side effect of azathioprine
- Reply
- Cutaneous manifestations associated with COVID-19 infection at a university hospital in eastern China
- 608 A clinical study to test the efficacy of VB1953 in clindamycin non-responder acne patients with antibiotic-resistant P. acnes
- 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
- TREATMENT OF SEVERE ALOPECIA AREATA USING METHOTREXATE AS AN ADJUNCTIVE DRUG IN COMBINATION WITH INTRAVENOUS AND ORAL CORTICOSTEROID
- Reversible Anagen Effluvium Induced by Azathioprine: A Rare Adverse Effect Case Report
- Dermatology practice in a high-tech world
- Clinico-etiological and histopathological correlation in erythroderma: In a tertiary care hospital of Eastern Odisha
- Latest Advances in Inflammatory Skin Disease
- Study of Paediatric Dermatology Consultations during COVID-19 Lockdown
- A Clinical Study on Cutaneous Manifestations of Obesity
- 609 Topical Sandalore®, a specific OR2AT4-stimulating odorant, ameliorates female telogen effluvium: Randomized, double-blinded, placebo-controlled clinical trial